Welcome to our dedicated page for Ekso Bionics news (Ticker: EKSO), a resource for investors and traders seeking the latest updates and insights on Ekso Bionics stock.
Ekso Bionics Holdings, Inc. (Symbol: EKSO) is a pioneering company in the field of robotic exoskeletons, or wearable robots, aimed at augmenting human strength, endurance, and mobility. Since its founding in 2005, Ekso Bionics has developed cutting-edge technology that has enabled thousands of people with paralysis to take millions of steps that would otherwise be impossible. Headquartered in Richmond, California, with international offices in London, the company has been a leader in both the healthcare and industrial markets.
Ekso Bionics operates through two main segments: EksoHealth and EksoWorks. The EksoHealth segment, which generates the majority of the company's revenue, focuses on designing, engineering, manufacturing, and selling exoskeletons for medical applications. These devices are worn over clothing and controlled by trained operators to assist individuals with mobility challenges. The EksoWorks segment, on the other hand, targets able-bodied users by creating exoskeleton devices that help them perform strenuous, repetitive tasks for extended periods.
Over the years, Ekso Bionics has been at the forefront of innovation, continuously pushing the boundaries of what robotic exoskeletons can achieve. Their products have not only redefined the scope of physical rehabilitation but have also found significant applications in various industrial settings, allowing workers to carry out challenging tasks more efficiently. Ekso Bionics is committed to breaking physical limitations and helping users reach new heights of capability.
For the latest updates, partnerships, and developments related to Ekso Bionics and their stock performance, visit StockTitan regularly.
Ekso Bionics (Nasdaq: EKSO) announced preliminary financial results for Q4 and FY 2020, with Q4 revenue estimated at $2.3 million, down from $3.7 million in Q4 2019. Total revenue for FY 2020 is about $8.9 million, compared to $13.9 million in 2019. Cash reserves rose to $12.9 million from $10.9 million year-over-year. CEO Jack Peurach highlighted strong performance despite COVID-19 challenges and a new subscription model aimed to expand their market. The company plans to report complete results in late February 2021.
Ekso Bionics (Nasdaq: EKSO) announced its participation in the H.C. Wainwright BioConnect 2021 Virtual Conference from January 11-14, 2021. Jack Peurach, CEO, and Jack Glenn, CFO, will present at this event. An on-demand company presentation will be available starting January 11 at 6:00 AM ET on the company's website. Ekso Bionics specializes in exoskeleton technology aimed at enhancing strength and mobility for medical and industrial applications, furthering its mission to amplify human potential.
Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) announced the election of Mary Ann Cloyd and Rhonda A. Wallen to its Board of Directors, effective December 29, 2020. Both directors bring extensive experience in business and healthcare. Cloyd has nearly 40 years of experience in public accounting and corporate governance, while Wallen has 25 years in life sciences and healthcare. Their insights are expected to enhance corporate strategy and value for stockholders as Ekso Bionics continues advancing its exoskeleton technology for medical and industrial applications.
Ekso Bionics Holdings (Nasdaq: EKSO) has announced a subscription-based order for its EVO exoskeleton from Cloverdale Foods Company, a family-owned meat company. This adoption highlights the effectiveness of EVO in reducing worker fatigue and enhancing productivity in the food processing sector. Cloverdale plans to implement the EVO Exoskeleton Program to ensure employee safety while meeting increased product demand. The EVO exoskeleton features a customized fit, reduced weight, and is rigorously tested for quality, aiming to enhance workplace efficiency and employee health.
Ekso Bionics (Nasdaq: EKSO) announced its Q3 financial results for 2020, reporting revenues of $2.9 million, a sequential increase from $2.3 million in Q2. Gross margins improved to 63% versus 53% a year earlier, attributed to higher selling prices and reduced production costs. Cash reserves stood at $14.5 million, bolstered by $2.5 million from warrant exercises. However, overall revenue decreased compared to last year due to COVID-19 impacts on sales. Despite challenges, the company launched the EVO exoskeleton, which received positive initial interest.
Ekso Bionics (Nasdaq: EKSO) has launched its innovative EVO exoskeleton, aimed at reducing fatigue-related injuries among industrial workers. EGM Builders is the first customer to adopt this technology, which offers lift assistance to alleviate physical strain during overhead tasks. The EVO device enhances worker safety and productivity, aligning with EGM Builders' commitment to employee well-being. Despite the promising features, the company faces potential risks, including market acceptance and competition, as indicated in their forward-looking statements.
Ekso Bionics announced it will release its third quarter 2020 financial results on October 29, 2020, after trading hours. A conference call will follow at 1:30 p.m. PT / 4:30 p.m. ET to discuss the outcomes and recent developments. Interested investors can join by calling 877-407-3036 (domestic) or 201-378-4919 (international), and a live webcast will be accessible on the company's website. A replay of the call will be available for two weeks post-event.
Ekso Bionics Holdings (Nasdaq: EKSO), a leader in exoskeleton technology, announced that CFO Jack Glenn will present at the H.C. Wainwright 22nd Annual Global Investment Virtual Conference on September 16, 2020, at 11:30 am ET. The presentation will highlight the company's advancements in exoskeleton solutions, aimed at enhancing human strength and mobility in various applications. A live and archived webcast will be available on the company's investor website.
Ekso Bionics reported financial results for Q2 2020, revealing revenue of $2.3 million, up from $1.5 million in Q1 but down from $3.3 million in Q2 2019. The company achieved a record gross margin of 56%, up from 48% year-over-year. Despite revenue growth from the previous quarter, a loss of $11.8 million was recorded, compared to $3.1 million in 2019. The firm raised $11.1 million in financing and received FDA clearance for its EksoNR robotic exoskeleton, expanding its market potential. However, revenue decline was attributed to COVID-19 impacts.
Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) announced that it will release its financial results for Q2 2020 on July 30, 2020, after market close. A conference call will follow at 1:30 p.m. PT / 4:30 p.m. ET to discuss the results and recent company developments. Investors can listen by dialing 877-407-3036 or via a live webcast on the company’s website. A replay will be available for two weeks. Ekso Bionics is a leader in exoskeleton technology, focusing on medical and industrial applications, and aims to enhance human mobility and endurance.
FAQ
What is the current stock price of Ekso Bionics (EKSO)?
What is the market cap of Ekso Bionics (EKSO)?
What does Ekso Bionics Holdings, Inc. do?
Where is Ekso Bionics headquartered?
What are the main segments of Ekso Bionics?
What does the EksoHealth segment specialize in?
What does the EksoWorks segment focus on?
How has Ekso Bionics impacted people with paralysis?
In which regions does Ekso Bionics operate?
How can I get in touch with Ekso Bionics for investor relations?
What innovations has Ekso Bionics brought to the industrial market?
How does Ekso Bionics contribute to physical rehabilitation?
